Roche is shifting its R&D focus towards major diseases like obesity and diabetes, responding to rising healthcare costs and government demands for cost-effective treatments. The company aims to develop transformative drugs for chronic illnesses, anticipating that these areas will account for over 50% of the global disease burden in the next decade. With the obesity drug market projected to exceed $100 billion annually by 2030, Roche's renewed investment includes a $2.7 billion acquisition of Carmot Therapeutics to bolster its cardiovascular-metabolic research.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
